Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 412

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Acamprosate for alcohol dependence

Open access
Rösner, Susanne, Hackl-Herrwerth, Andrea, Leucht, Stefan, Lehert, Philippe, Vecchi, Simona, Soyka, Michael·2010·Cochrane Database of Systematic Reviews
DOI 10.1002/14651858.cd004332.pub2
Open this paper in CoChat — free account

Abstract

BACKGROUND: Alcohol dependence is among the main leading health risk factors in most developed and developing countries. Therapeutic success of psychosocial programs for relapse prevention is moderate, but could potentially be increased by an adjuvant treatment with the glutamate antagonist acamprosate. OBJECTIVES: To determine the effectiveness and tolerability of acamprosate in comparison to placebo and other pharmacological agents. SEARCH STRATEGY: We searched the Cochrane Drugs and Alcohol Group (CDAG) Specialized Register, PubMed, EMBASE and CINAHL in January 2009 and inquired manufacturers and researchers for unpublished trials. SELECTION CRITERIA: All double-blind randomised controlled trials (RCTs) which compare the effects of acamprosate with placebo or active control on drinking-related outcomes. DATA COLLECTION AND ANALYSIS: Two authors independently extracted data. Trial quality was assessed by one author and cross-checked by a second author. Individual patient data (IPD) meta-analyses were used to verify the primary effectiveness outcomes. MAIN RESULTS: 24 RCTs with 6915 participants fulfilled the criteria of inclusion and were included in the review. Compared to placebo, acamprosate was shown to significantly reduce the risk of any drinking RR 0.86 (95% CI 0.81 to 0.91); NNT 9.09 (95% CI 6.66 to 14.28) and to significantly increase the cumulative abstinence duration MD 10.94 (95% CI 5.08 to 16.81), while secondary outcomes (gamma-glutamyltransferase, heavy drinking) did not reach statistical significance. Diarrhea was the only side effect that was more frequently reported under acamprosate than placebo RD 0.11 (95% 0.09 to 0.13); NNTB 9.09 (95% CI 7.69 to 11.11). Effects of industry-sponsored trials RR 0.88 (95% 0.80 to 0.97) did not significantly differ from those of non-profit funded trials RR 0.88 (95% CI 0.81 to 0.96). In addition, the linear regression test did not indicate a significant risk of publication bias (p = 0.861). AUTHORS' CONCLUSIONS: Acamprosate appears to be an effective and safe treatment strategy for supporting continuous abstinence after detoxification in alcohol dependent patients. Even though the sizes of treatment effects appear to be rather moderate in their magnitude, they should be valued against the background of the relapsing nature of alcoholism and the limited therapeutic options currently available for its treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd004332.pub2

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 114

  1. Anton, 2006, Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomised controlled trial, JAMA, 295, 2003, 10.1001/jama.295.17.2003 · DOI · Paper page
  2. Baltieri, 2004, Acamprosate in alcohol dependence: a randomised controlled efficacy study in a standard clinical setting, Journal of studies on alcohol, 65, 136, 10.15288/jsa.2004.65.136 · DOI
  3. Barrias, 1997, Acamprosate: multicenter Portuguese efficacy and tolerance evaluation study, Psiquiatria Clinica, 18, 149
  4. Besson, 1998, Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study, Alcoholism, Clinical and Experimental Research, 22, 573, 10.1111/j.1530-0277.1998.tb04295.x · DOI · Paper page
  5. Chick, 2000, United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol, Alcohol and Alcoholism, 35, 176, 10.1093/alcalc/35.2.176 · DOI · Paper page
  6. Geerlings, 1997, Acamprosate and prevention of relapse in alcoholics. Results of a randomised, placebo-controlled, double-blind study in out-patient alcoholics in The Netherlands, Belgium and Luxembourg, European Addiction Research, 3, 129, 10.1159/000259166 · DOI
  7. Gual, 2001, Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain, Alcohol and Alcoholism, 36, 413, 10.1093/alcalc/36.5.413 · DOI
  8. Kiefer, 2003, Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study, Archives of General Psychiatry, 60, 92, 10.1001/archpsyc.60.1.92 · DOI · Paper page
  9. Ladewig, 1993, Acamprosate--a stabilizing factor in long-term withdrawal of alcoholic patients, Therapeutische Umschau, 50, 182
  10. Lhuintre, 1985, Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics, Lancet, 1, 1014, 10.1016/S0140-6736(85)91615-0 · DOI · Paper page
  11. Lhuintre, 1990, Acamprosate appears to decrease alcohol intake in weaned alcoholics, Alcohol and Alcoholism, 25, 613, 10.1093/oxfordjournals.alcalc.a045057 · DOI · Paper page
  12. Mason, 2006, Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation, Journal of Psychiatric Research, 40, 383, 10.1016/j.jpsychires.2006.02.002 · DOI · Paper page
  13. Morley, 2006, Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomised, double-blind, placebo-controlled trial, Addiction, 101, 1451, 10.1111/j.1360-0443.2006.01555.x · DOI · Paper page
  14. Namkoong, 2003, Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomised, double-blind, placebo-controlled study, Alcohol and Alcoholism, 38, 135, 10.1093/alcalc/agg038 · DOI
  15. Niederhofer, 2003, Acamprosate and its efficacy in treating alcohol dependent adolescents, European Child & Adolescent Psychiatry, 12, 144, 10.1007/s00787-003-0327-1 · DOI
  16. Paille, 1995, Double-blind randomised multi centre trial of acamprosate in maintaining abstinence from alcohol, Alcohol and Alcoholism, 30, 239
  17. Pelc, 1992, Acamprosate in the treatment of alcohol dependence: A six month post detoxification study, 348, 10.1007/978-1-4612-2878-3_44 · DOI
  18. Pelc, 1997, Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study, British Journal of Psychiatry, 171, 73, 10.1192/bjp.171.1.73 · DOI · Paper page
  19. Poldrugo, 1997, Acamprosate treatment in a long-term community-based alcohol rehabilitation programme, Addiction, 92, 1537, 10.1111/j.1360-0443.1997.tb02873.x · DOI
  20. Roussaux, 1996, Does acamprosate diminish the appetite for alcohol in weaned alcoholics?, Journal de Pharmacie de Belgique, 51, 65
  21. Sass, 1996, Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence, Archives of General Psychiatry, 53, 673, 10.1001/archpsyc.1996.01830080023006 · DOI · Paper page
  22. Tempesta, 2000, Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study, Alcohol and Alcoholism, 35, 202, 10.1093/alcalc/35.2.202 · DOI
  23. Whitworth, 1996, Comparison of acamprosate and placebo in long-term treatment of alcohol dependence, Lancet, 347, 1438, 10.1016/S0140-6736(96)91682-7 · DOI · Paper page
  24. Boeijinga, 2004, Pharmacodynamic effects of acamprosate on markers of cerebral function in alcohol-dependent subjects administered as pretreatment and during alcohol abstinence, Neuropsychobiology, 50, 71, 10.1159/000077944 · DOI
  25. Buri, 2007, Prescription procedures in medication for relapse prevention after inpatient treatment for alcohol use disorders in Switzerland, Alcohol and Alcoholism, 42, 333, 10.1093/alcalc/agm038 · DOI
  26. Croissant, 2006, A pilot study of oxcarbazepine versus acamprosate in alcohol-dependent patients, Alcoholism: Clinical and Experimental Research, 30, 630, 10.1111/j.1530-0277.2006.00082.x · DOI
  27. Wildt, 2002, Does psychosocial treatment enhance the efficacy of acamprosate in patients with alcohol problems?, Alcohol and Alcoholism, 37, 375, 10.1093/alcalc/37.4.375 · DOI
  28. Feeney, 2002, Cognitive behavioural therapy combined with the relapse-prevention medication acamprosate: are short-term treatment outcomes for alcohol dependence improved?, Australian and New Zealand Journal of Psychiatry, 36, 622, 10.1046/j.1440-1614.2002.01019.x · DOI
  29. Florez, 2008, Using topiramate or naltrexone for the treatment of alcohol-dependent patients, Alcoholism: Clinical and Experimental Research, 32, 1251, 10.1111/j.1530-0277.2008.00680.x · DOI
  30. Fuchs, 2002, Acamprosate and psychosocial intervention. An integrative treatment approach for prevention of alcohol dependent patients in Switzerland, Praxis (Bern 1994), 91, 735, 10.1024/0369-8394.91.17.735 · doi:10.1024/0369-8394.91.17.735
  31. Gerra, 1992, Effects of fluoxetine and Ca-acetyl-homotaurinate on alcohol intake in familial and nonfamilial, Current Therapeutic Research, 52, 291, 10.1016/S0011-393X(05)80480-1 · DOI
  32. Hammarberg, 2004, A comparison of two intensities of psychosocial intervention for alcohol dependent patients treated with acamprosate, Alcohol and Alcoholism, 39, 251, 10.1093/alcalc/agh056 · DOI
  33. Han, 2008, The effect of acamprosate on alcohol and food craving in patients with alcohol dependence, Drug and Alcohol Dependence, 93, 279, 10.1016/j.drugalcdep.2007.09.014 · DOI
  34. Johnson, 2003, Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects, Journal of Clinical Psychopharmacoly, 23, 281, 10.1097/01.jcp.0000084029.22282.bb · DOI
  35. Kampman, 2009, Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependence, Addictive Behaviors, 34, 581, 10.1016/j.addbeh.2009.03.014 · DOI
  36. Kiritze-Topor, 2004, A pragmatic trial of acamprosate in the treatment of alcohol dependence in primary care, Alcohol and Alcoholism, 39, 520, 10.1093/alcalc/agh088 · DOI
  37. Laaksonen, 2008, A randomised, multi centre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence, Alcohol and Alcoholism, 43, 53, 10.1093/alcalc/agm136 · DOI
  38. Mason, 2002, A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone, Neuropsychopharmacology, 27, 596, 10.1016/S0893-133X(02)00368-8 · DOI
  39. Nespor, 2006, Treatment and prevention of alcohol-related problems and evidence based medicine, Casopis Lekaru Ceskych, 145, 964
  40. Ooteman, 2007, The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics, European Neuropsychopharmacoly, 17, 558, 10.1016/j.euroneuro.2007.02.012 · DOI
  41. Pelc, 2002, The European NEAT program: an integrated approach using acamprosate and psychosocial support for the prevention of relapse in alcohol-dependent patients with a statistical modelling of therapy success prediction, Alcoholism Clinical and Experimental Research, 26, 1529, 10.1111/j.1530-0277.2002.tb02452.x · DOI
  42. Reid, 2005, The efficacy of compliance therapy in pharmacotherapy for alcohol dependence: a randomised controlled trial, Journal of Studies on Alcohol, 66, 833, 10.15288/jsa.2005.66.833 · DOI
  43. Rubio, 2001, Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment, Alcohol and Alcoholism, 36, 419, 10.1093/alcalc/36.5.419 · DOI
  44. Rychlik, 2001, Adjuvant drug treatment of alcoholism with acamprosate: between sectorial budgets and disease management, Deutsche Medizinische Wochenschrift, 126, 899, 10.1055/s-2001-16502 · doi:10.1055/s-2001-16502
  45. Soyka, 2002, Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism. Results from a non-blind, multicentre study, Drugs in Road Traffic, 3, 1
  46. Staner, 2006, Effects of acamprosate on sleep during alcohol withdrawal: A double-blind placebo-controlled polysomnographic study in alcohol-dependent subjects, Alcoholism: Clinical and Experimental Research, 30, 1492, 10.1111/j.1530-0277.2006.00180.x · DOI
  47. Alonso, 2004, Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project, Acta Psychiatrica Scandinavia Supplement, 420, 21
  48. Arroll, 2009, Antidepressants versus placebo for depression in primary care, Cochrane Database of Systematic Reviews, 10.1002/14651858 · doi:10.1002/14651858
  49. Bachteler, 2005, The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat, Neuropsychopharmacology, 30, 1104, 10.1038/sj.npp.1300657 · DOI
  50. Berglund MA Franck J Fridell M Hakanson I Johansson BA Treatment of alcohol and drug abuse - an evidence-based review Swedish Council on Technology Assessment in Health Care (SBU) 2003
  51. Bouza, 2004, Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review, Addiction, 99, 811, 10.1111/j.1360-0443.2004.00763.x · DOI · Paper page
  52. Brockwell, 2001, A comparison of statistical methods for meta-analysis, Statistics in Medicine, 20, 825, 10.1002/sim.650 · DOI · Paper page
  53. Cano-Cebrian, 2003, Acamprosate blocks the increase in dopamine extracellular levels in nucleus accumbens evoked by chemical stimulation of the ventral hippocampus, Naunyn Schmiedebergs Archives of Pharmacology, 368, 324, 10.1007/s00210-003-0795-3 · DOI
  54. Chick, 2003, Does acamprosate improve reduction of drinking as well as aiding abstinence?, Journal of Psychopharmacology, 17, 397, 10.1177/0269881103174017 · DOI
  55. Citrome, 2008, Compelling or irrelevant? Using number needed to treat can help decide, Acta Psychiatrica Scandinavia, 117, 412, 10.1111/j.1600-0447.2008.01194.x · DOI
  56. Cole, 2000, Acamprosate, but not naltrexone, inhibits conditioned abstinence behaviour associated with repeated ethanol administration and exposure to a plus-maze, Psychopharmacology (Berl), 147, 403, 10.1007/s002130050009 · DOI · Paper page
  57. Czachowski, 2001, Effects of acamprosate on ethanol-seeking and self-administration in the rat, Alcoholism Clinical and Experimental Research, 25, 344
  58. DerSimonian, 1986, Meta-analysis in clinical trials, Controlled Clinical Trials, 7, 177, 10.1016/0197-2456(86)90046-2 · DOI · Paper page
  59. Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629 · DOI · Paper page
  60. Heyser, 1998, Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats, Neuropsychopharmacology, 18, 125, 10.1016/S0893-133X(97)00130-9 · DOI · Paper page
  61. Higgins, 2001, Meta-analysis of continuous outcome data from individual patients, Statistics in Medicine, 20, 2219, 10.1002/sim.918 · DOI · Paper page
  62. Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
  63. Hopkins, 2002, Naltrexone and acamprosate: Meta-analysis of two medical treatments for alcoholism, Alcoholism: Clinical and Experimental Research, 26, 130A
  64. Huwiler-Muntener, 2002, Quality of reporting of randomised trials as a measure of methodologic quality, JAMA, 287, 2801, 10.1001/jama.287.21.2801 · DOI · Paper page
  65. International Conference on Harmonisation Guideline for Good ClinicalPractice E6(R1). (http://www.ich.org/LOB/media/MEDIA482.pdf) 1996
  66. Kadden, 1992, Cognitive-Behavioral Coping Skills Therapy Manual: A Clinical Research Guide fro Therapists Treating Individuals with Alcohol Abuse and Dependence, 3
  67. Keller, 1972, On the loss-of-control phenomenon in alcoholism, British Journal of Addiction, 67, 153
  68. Kiefer, 2004, Long-term effects of pharmacotherapy on relapse prevention in alcohol dependence, Acta Neuropsychiatrica, 16, 233, 10.1111/j.0924-2708.2004.00093.x · DOI
  69. Konnopka, 2007, Direct and indirect costs attributable to alcohol consumption in Germany, Pharmacoeconomics, 25, 605, 10.2165/00019053-200725070-00006 · DOI
  70. Kranzler, 2001, Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis, Alcoholism: Clinical and Experimental Research, 25, 1335
  71. Lefebvre, 2008, Chapter 6: Searching for Studies, 95, 10.1002/9780470712184.ch6 · DOI · Paper page
  72. Lehert, 1993, Review and discussion of statistical analysis of controlled clinical trials in alcoholism, Alcohol and Alcoholism Supplement, 2, 157
  73. LeMagnen, 1987, Lack of effects of Ca-acetyl homotaurinate on chronic and acute toxicities of ethanol in rats, Alcohol and Alcohilsm, 4, 103, 10.1016/0741-8329(87)90006-1 · DOI
  74. Levine, 1986, SAFTEE: a technique for the systematic assessment of side effects in clinical trials, Psychopharmacol Bulletin, 22, 343
  75. Light, 1984, The science of reviewing research, 10.4159/9780674040243 · DOI · Paper page
  76. Littleton, 1995, Acamprosate in alcohol dependence: how does it work?, Addiction, 90, 1179, 10.1111/j.1360-0443.1995.tb01088.x · DOI · Paper page
  77. Littleton, 2003, Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence, American Journal of Addiction, 12 Supplement 1, 3
  78. Mann, 2004, The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis, Alcoholism: Clinical and Experimental Research, 28, 51, 10.1097/01.ALC.0000108656.81563.05 · DOI · Paper page
  79. Mann, 2008, Acamprosate: recent findings and future research directions, Alcoholism: Clinical and Experimental Research, 32, 1105, 10.1111/j.1530-0277.2008.00690.x · DOI
  80. Marlatt, 1985, Relapse prevention
  81. McGeehan, 2003, The anti-relapse compound acamprosate inhibits the development of a conditioned place preference to ethanol and cocaine but not morphine, British Journal of Pharmacology, 138, 9, 10.1038/sj.bjp.0705059 · DOI
  82. McQueen, 2009, Brief interventions for heavy alcohol users admitted to general hospital wards, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD005191.pub2 · DOI
  83. Miller, 1994, Motivational Enhancement Therapy manual: A clinical research guide for therapists treating individuals with alcohol abuse and dependence
  84. Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLoS Med, 6, e1000097, 10.1371/journal.pmed.1000097 · DOI · Paper page
  85. Moncrieff, 2004, Active placebos versus antidepressants for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858 · doi:10.1002/14651858
  86. Moos, 2006, Rates and predictors of relapse after natural and treated remission from alcohol use disorders, Addiction, 101, 212, 10.1111/j.1360-0443.2006.01310.x · DOI · Paper page
  87. Naassila, 1998, Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain, Alcoholism: Clinical and Experimental Research, 22, 802, 10.1111/j.1530-0277.1998.tb03871.x · doi:10.1111/j.1530-0277.1998.tb03871.x · Paper page
  88. Nickerson, 1998, Confirmation Bias: A Ubiquitous Phenomenon, Review of General Psychology, 2, 175, 10.1037/1089-2680.2.2.175 · DOI · Paper page
  89. Nowinski, 1995, Twelve Step Facilitation Therapy manual. A clinical research guide for therapists treating individuals with alcohol abuse and dependence
  90. Olive, 2002, Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release, European Journal of Pharmacology, 437, 55, 10.1016/S0014-2999(02)01272-4 · DOI
  91. Pettinati, 2004, Medical Management Treatment Manual. A Clinical Research Guide for MedicallyTrained Clinicians Providing Pharmacotherapy as Part of the Treatment for AlcoholDependence, 2
  92. Pildal, 2007, Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials, International Journal of Epidemiology, 36, 847, 10.1093/ije/dym087 · DOI · Paper page
  93. Pocock, 1987, Statistical problems in the reporting of clinical trials. A survey of three medical journals, New England Journal of Medicine, 317, 426, 10.1056/NEJM198708133170706 · DOI · Paper page
  94. Rabkin, 1992, General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research, Journal of Clinical Psychopharmacology, 12, 3, 10.1097/00004714-199202000-00002 · DOI
  95. Riley, 2007, Evidence synthesis combining individual patient data and aggregate data: a systematic review identified current practice and possible methods, Journal of Clinical Epidemiology, 60, 431, 10.1016/j.jclinepi.2006.09.009 · DOI · Paper page
  96. Rösner, 2008, Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes, Journal of Psychopharmacology, 22, 11, 10.1177/0269881107078308 · DOI · Paper page
  97. Rücker, 2008, Undue reliance on I(2) in assessing heterogeneity may mislead, BMC Medical Research Methodology, 8, 79, 10.1186/1471-2288-8-79 · DOI · Paper page
  98. Schoechlin, 2000, Meta-analysis of pharmacotherapeutic trials, 339, 10.1201/9781420036961.ch31 · DOI
  99. Schulz, 1995, Subverting randomisation in controlled trials, JAMA, 274, 1456, 10.1001/jama.1995.03530180050029 · DOI · Paper page
  100. Selzer, 1971, The Michigan Alcoholism Screening Test (MAST): The quest for a new diagnostic instrument, American Journal of Psychiatry, 127, 1653, 10.1176/ajp.127.12.1653 · DOI · Paper page
  101. Skinner, 1982, Alcohol dependence syndrome: measurement and validation, Journal of Abnormal Psychology, 91, 199, 10.1037/0021-843X.91.3.199 · DOI · Paper page
  102. Skinner, 1984, Alcohol Dependence Scale: Users Guide
  103. Sobell, 1988, The reliability of alcohol abusers' self-reports of drinking and life events that occurred in the distant past, Journal of Studies on Alcohol, 49, 225, 10.15288/jsa.1988.49.225 · DOI · Paper page
  104. Sobell, 1992, Alcohol abusers' perceptions of the accuracy of their self-reports of drinking: implications for treatment, Addictive Behaviors, 17, 507, 10.1016/0306-4603(92)90011-J · DOI
  105. Spanagel, 1996, Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat, European Journal of Pharmacology, 305, 39, 10.1016/0014-2999(96)00174-4 · DOI · Paper page
  106. Spanagel, 1997, Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes, Trends in Pharmacological Sciences, 18, 54, 10.1016/S0165-6147(97)89800-8 · DOI · Paper page
  107. Spanagel, 2003, Acamprosate--new preclinical research aspects, MMW, Fortschritte der Medizin, 145 Supplement, 61
  108. Srisurapanont, 2005, Opioid antagonists for alcohol dependence, Cochrane Database of Systematic Reviews, 10.1002/14651858 · doi:10.1002/14651858
  109. Tannock, 1996, False-positive results in clinical trials: multiple significance tests and the problem of unreported comparisons, Journal of the National Cancer Institute, 88, 206, 10.1093/jnci/88.3-4.206 · DOI
  110. The Nordic Cochrane Centre Review Manager (RevMan). 5.0 2008
  111. Turner, 2000, A multilevel model framework for meta-analysis of clinical trials with binary outcomes, Statistics in Medicine, 19, 3417, 10.1002/1097-0258(20001230)19:24<3417::AID-SIM614>3.0.CO;2-L · DOI · Paper page
  112. Verheul, 2005, Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients, Psychopharmacology (Berl), 178, 167, 10.1007/s00213-004-1991-7 · DOI
  113. Zeise, 1993, Acamprosate (calciumacetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors, European Jorunal of Pharmacology, 231, 47, 10.1016/0014-2999(93)90682-8 · DOI · Paper page
  114. Zornoza, 2003, Pharmacology of acamprosate: an overview, CNS Drug Reviews, 9, 359, 10.1111/j.1527-3458.2003.tb00260.x · DOI

Cited by

See all 412

Metadata

Authors
Rösner, S., Hackl-Herrwerth, A., Leucht, S., Lehert, P., Vecchi, S., & Soyka, M.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2010-09-07
Volume
2011
Issue
2
Pages
70-2
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
DOI
10.1002/14651858.cd004332.pub2
OpenAlex
W1966583118
Cited by
412
References
15
FWCI
18.24
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acamprosate for alcohol dependence. https://app.cochat.ai/papers/10.1002/14651858.cd004332.pub2
The paper
Rösner, S., Hackl-Herrwerth, A., Leucht, S., Lehert, P., Vecchi, S., & Soyka, M. (2010). Acamprosate for alcohol dependence. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd004332.pub2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.